ER、PR、C-erbB-2、E—Cad、p53、Ki-67在乳腺癌组织中的表达及意义

The expressions of ER, PR, C-erbB-2, E-Cad, p53 and Ki-67 in breast cancer and their clinical significance

目的探讨ER、PR、C-erbB-2、E—Cad、p53、Ki-67在乳腺癌组织中的表达及其与临床病理的关系。方法采用免疫组织化学SP法检测80例乳腺癌患者癌组织中ER、PR、C—erbB-2、E．Cad、p53、Ki-67的蛋白表达，并结合临床和病历资料进行分析。结果ER、PR、C—erbB-2、E—Cad、p53、Ki-67在乳腺癌中的阳性表达率依次为60．0％、57．5％、45．0％、80．0％、48．8％、82．5％；除C—erbB-2与淋巴结转移存在明显相关性外，其他五项指标与患者年龄、淋巴结转移、肿块大小和病理分级无显著相关性。结论ER、PR、C．erbB-2、E—Cad、p53、Ki-67在乳腺癌中的表达有一定相关性，联合检测对乳腺癌的治疗及预后评估有一定的价值。

Objective To explore the expressions of ER, PR, C-erbB-2, E-Cad, p53 and Ki-67 in breast cancer and their relationship with elinieopathology. Methods The expressions of ER, PR, C-erbB-2, E-Cad, p53 and Ki-67 proteins were detected in 80 cases of patients with breast cancer using immunohistochemical Streptavidin-Pero- sidase（SP） method,and were analyzed with clinical and medical records. Results The positive expression rates of ER,PR, C-erbB-2, E-Cad, p53 and Ki-67 in breast cancer were 60.0% , 57.5% , 45.0% , 80.0% , 48.8% and 82. 5% ,respectively. In addition to C-erbB-2 which had correlation with lymph node metastasis, other five indicators showed no significant correlations with patient age, lymph node metastasis, tumor size and pathological grade. Conclusion There is a certain correlation in the expressions of ER, PR, C-erbB-2, E-Cad, p53 and Ki-67 in breast cancer. Combined detection is valuable in the treatment and prognostic evaluation of breast cancer.